CCC
BIO icon

Crescent Capital Consulting’s Bio-Rad Laboratories Class A BIO Stock Holding History

Crescent Capital Consulting’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$5K Hold
6
– – ﹤0.01% 430
2021
Q3 		$4K Hold
6
– – ﹤0.01% 469
2021
Q2 		$4K Buy
+6
New +$3.65K ﹤0.01% 412

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Crescent Capital Consulting's BIO Position: Q4 2021 in Review

Crescent Capital Consulting held its Bio-Rad Laboratories Class A (BIO) position steady in Q4 2021 at 6 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #430.

Crescent Capital Consulting first reported a position in BIO in Q2 2021 and has held it in 3 quarters since. 533 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

  • Crescent Capital Consulting held 6 shares of Bio-Rad Laboratories Class A worth $5K as of Q4 2021.
  • Crescent Capital Consulting left its Bio-Rad Laboratories Class A share count unchanged in Q4 2021.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #430 holding.
  • Crescent Capital Consulting first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and has held it in 3 quarters since.
  • 533 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.